Oragenics Regains NYSE Compliance While Advancing Neurological Therapeutics Pipeline
Oragenics Inc. has regained full NYSE American compliance while making significant progress toward its first clinical trial and expanding its neurological therapeutics pipeline through an AI-driven collaboration with Receptor.AI.
